Monogenic Disorder Testing in Pakistan at Chughtai Lab

Monogenic Disorder Testing at Chughtai Lab

Monogenic disorders, also known as single-gene disorders, are medical conditions caused by pathogenic variants or mutations within a single gene. Unlike multifactorial diseases that result from a combination of lifestyle, environmental factors, and multiple genetic variations, monogenic disorders follow classic Mendelian inheritance patterns. These include autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive, and mitochondrial inheritance. Understanding and diagnosing these disorders is critical for clinical management, reproductive planning, and family counseling. Monogenic disorder testing at Chughtai Lab utilizes state-of-the-art molecular biology techniques to identify these specific genetic alterations, providing patients and clinicians with definitive diagnostic answers.

The molecular diagnostic division at Chughtai Lab employs advanced technologies such as Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Sanger sequencing, and Multiplex Ligation-dependent Probe Amplification (MLPA). These technologies allow molecular pathologists to analyze the patient’s genomic DNA with exceptional precision. The test evaluates specific regions of the genome, targeting single nucleotides, small insertions or deletions (indels), or copy number variations (CNVs) depending on the clinical presentation and the specific gene under investigation. By identifying the precise genetic etiology, this testing plays an indispensable role in confirming clinical diagnoses, predicting disease progression, and guiding targeted therapeutic interventions.

The clinical importance of monogenic disorder testing cannot be overstated. For many inherited conditions, clinical symptoms can overlap significantly, making a purely physical or symptomatic diagnosis challenging. Molecular testing provides a definitive, objective diagnosis that can prevent unnecessary diagnostic procedures, optimize treatment strategies, and offer accurate prognostic information. Furthermore, identifying a monogenic mutation in an index patient (proband) allows for cascade testing of at-risk family members, enabling early intervention, lifestyle modifications, or informed reproductive choices, such as pre-implantation genetic testing or prenatal diagnosis.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure the integrity of the genetic sample and the accuracy of the clinical interpretation. Patients undergoing monogenic disorder testing at Chughtai Lab should observe the following guidelines:

• Clinical Documentation: Patients must provide a detailed clinical history, including a comprehensive three-generation family pedigree, previous laboratory findings, and any relevant clinical reports. This information is vital for the molecular pathologist to interpret genetic variants accurately.
• Informed Consent: Genetic testing requires formal, written informed consent. Patients or their legal guardians must sign a consent form acknowledging they understand the purpose, benefits, limitations, and potential psychological or social implications of genetic testing.
• Dietary Restrictions: For standard peripheral blood samples, fasting is generally not required. Patients may eat and drink normally prior to sample collection. However, if a saliva or buccal swab is used, patients must avoid eating, drinking, smoking, or chewing gum for at least 30 minutes before sample collection.
• Medication History: It is important to inform the laboratory staff of any recent blood transfusions (within the last 3 months) or bone marrow transplants, as these can introduce donor DNA and interfere with the accuracy of the genetic analysis.
• Genetic Counseling: It is highly recommended that patients undergo pre-test genetic counseling with a qualified genetic counselor or medical specialist to fully understand the scope and possible outcomes of the test.

During the Procedure

The collection of biological material for monogenic disorder testing is a straightforward and minimally invasive procedure. The process is conducted under strict sterile conditions to prevent sample contamination:

• Sample Collection: The primary sample type for monogenic disorder testing is peripheral venous blood. A trained phlebotomist will locate a suitable vein, typically in the antecubital fossa of the arm, cleanse the area with an antiseptic solution, and perform a standard venipuncture.
• Equipment and Collection Tubes: Blood is collected into ethylenediaminetetraacetic acid (EDTA) tubes (purple top), which preserve the cellular components and prevent DNA degradation. For pediatric or neonatal patients where venipuncture is challenging, alternative samples such as saliva, buccal swabs, or dried blood spots may be utilized.
• Safety and Comfort: The venipuncture process takes only a few minutes and is associated with minimal discomfort, similar to a brief pinprick. Standard safety protocols are strictly followed to ensure patient safety and prevent cross-contamination.
• Accessioning and Chain of Custody: Once collected, the sample is immediately labeled with unique patient identifiers, barcoded, and entered into the laboratory information management system (LIMS) to maintain an unbroken chain of custody from collection to reporting.
• DNA Extraction and Analysis: In the molecular laboratory, genomic DNA is extracted from the white blood cells. The extracted DNA undergoes quality control assessments before being subjected to the designated molecular analysis, such as target gene sequencing or comprehensive gene panels.

When is a Monogenic Disorder Test Performed?

Family History of Inherited Genetic Conditions

Physicians frequently order monogenic disorder testing when there is a known or suspected hereditary condition within a family. If a relative has been diagnosed with a single-gene disorder such as Thalassemia, Cystic Fibrosis, or Huntington’s disease, family members may seek testing to determine their carrier status or risk of developing the condition. Identifying carrier status is particularly crucial for autosomal recessive disorders, where two carrier parents have a 25% risk of passing the condition to their offspring. Testing helps in risk assessment and guides reproductive planning.

Preconception and Prenatal Screening

Monogenic testing is widely performed during the preconception phase or early pregnancy, especially in regions with high rates of consanguinity. Couples planning a pregnancy may undergo carrier screening to identify if they carry mutations for the same recessive disorders. If a high risk is identified, prenatal diagnostic testing (such as chorionic villus sampling or amniocentesis) can be performed during pregnancy to determine if the fetus has inherited the pathogenic variants, allowing parents and obstetricians to make informed management decisions.

Unexplained Pediatric Developmental Delays or Congenital Anomalies

Pediatricians and clinical geneticists utilize monogenic testing to investigate infants and children presenting with unexplained developmental delays, intellectual disabilities, dysmorphic features, or multiple congenital anomalies. Many metabolic, neurological, and structural disorders of childhood are monogenic in origin. Establishing a molecular diagnosis early in life is critical for initiating early intervention programs, securing targeted medical therapies, avoiding unnecessary diagnostic pathways, and providing the family with accurate recurrence risks for future pregnancies.

Neuromuscular and Neurodegenerative Symptoms

Adults or children presenting with progressive muscle weakness, loss of motor coordination, cognitive decline, or involuntary movements often undergo monogenic testing to rule out hereditary neuromuscular or neurodegenerative conditions. Disorders such as Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, and various hereditary neuropathies are caused by specific single-gene mutations. Confirming the genetic basis of these symptoms helps differentiate them from acquired or autoimmune conditions, enabling appropriate clinical management and access to clinical trials.

Atypical Clinical Presentations of Metabolic Disorders

When a patient exhibits biochemical abnormalities suggestive of an inborn error of metabolism—such as persistent metabolic acidosis, hyperammonemia, or abnormal amino acid profiles—but the clinical picture remains ambiguous, monogenic testing is performed. Sequencing specific metabolic gene panels can pinpoint the exact enzyme deficiency. This precise identification allows for the immediate implementation of dietary modifications, enzyme replacement therapies, or specific pharmacological interventions that can prevent irreversible organ damage or life-threatening metabolic crises.

What Does a Monogenic Disorder Test Detect?

Monogenic disorder testing is designed to detect a wide spectrum of genetic variations within targeted genes. Depending on the clinical indication and the specific molecular assay used, the test can identify:

• Pathogenic Single Nucleotide Variants (SNVs): Highly specific changes where a single nucleotide base is substituted, inserted, or deleted, leading to altered protein structure or function.
• Nonsense Mutations: Premature stop codons that result in truncated, non-functional proteins.
• Missense Mutations: Amino acid substitutions that can alter protein folding, stability, or enzymatic activity.
• Frameshift Mutations: Insertions or deletions of nucleotides (not in multiples of three) that disrupt the reading frame of the gene, leading to completely altered downstream protein sequences.
• Splice-Site Variants: Mutations at exon-intron boundaries that interfere with correct pre-mRNA splicing, resulting in abnormal transcripts.
• Copy Number Variations (CNVs): Large-scale deletions or duplications of entire exons or genes, commonly evaluated in conditions like Duchenne Muscular Dystrophy.
• Trinucleotide Repeat Expansions: Abnormal increases in the number of specific three-nucleotide repeats, characteristic of disorders like Huntington’s disease and Fragile X syndrome.
• Autosomal Recessive Carrier Status: Identification of a single pathogenic variant in a gene associated with a recessive condition (e.g., Beta-Thalassemia trait).
• Homozygous Pathogenic Variants: Two identical mutated alleles at a specific locus, confirming an autosomal recessive disease.
• Compound Heterozygous Variants: Two different pathogenic mutations in the same gene, one on each chromosome, resulting in autosomal recessive disease expression.
• Heterozygous Dominant Variants: A single mutated allele sufficient to cause an autosomal dominant disorder.
• Hemizygous Mutations: Mutations on the single X chromosome in males, confirming X-linked conditions like Hemophilia or G6PD deficiency.
• Variants of Uncertain Significance (VUS): Genetic alterations where the clinical impact is currently unknown due to insufficient scientific evidence.
• Likely Pathogenic Variants: Genetic changes with high probability (typically >90%) of causing disease based on current clinical databases and computational models.
• Likely Benign and Benign Variants: Genetic variations that do not affect protein function and are considered normal human diversity.
• Mitochondrial DNA Mutations: Variants in the mitochondrial genome, which are maternally inherited and affect cellular energy production.
• De Novo Mutations: Newly arising mutations in the patient that were not inherited from either parent.
• Regulatory Region Mutations: Variants in promoter or enhancer regions that affect gene expression levels.
• Gene-Specific Deletions: Complete absence of a specific gene, leading to haploinsufficiency.
• Gene Duplications: Extra copies of a gene that can lead to overexpression and subsequent clinical pathology.

Turnaround Time and Report Access at Chughtai Lab

Due to the highly complex nature of molecular diagnostics and genetic sequencing, the turnaround time for monogenic disorder testing is typically longer than routine biochemical analyses. Depending on the specific gene panel, sequencing depth, and methodology utilized, results are generally available within several weeks. This timeframe ensures that rigorous quality control, sequence alignment, variant annotation, and clinical interpretation by a multidisciplinary team of molecular pathologists and geneticists are meticulously completed.

Chughtai Lab offers convenient and secure methods for patients and referring physicians to access diagnostic reports. Once the clinical report is finalized and verified, patients receive an automated SMS notification. Reports can be accessed online via the official Chughtai Lab web portal or through the user-friendly “My Chughtai” mobile application. This digital access ensures that patients can easily retrieve and share their genetic findings with their healthcare providers, facilitating prompt clinical decision-making and consultation.

Monogenic Disorder Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
HBB Gene (Beta-Globin)	Wild-type sequence; normal hemoglobin synthesis	Pathogenic variants (e.g., IVS-1-5, Fr 8-9) indicating Beta-Thalassemia or Sickle Cell Anemia
CFTR Gene	No pathogenic variants detected; normal chloride channel function	F508del or other pathogenic mutations confirming Cystic Fibrosis or carrier status
DMD Gene	Normal exon copy number; intact dystrophin protein coding	Exon deletions, duplications, or point mutations indicating Duchenne or Becker Muscular Dystrophy
HTT Gene	CAG repeat size within normal range (<27 repeats)	Expanded CAG repeats (>36 repeats) confirming Huntington’s Disease
SMN1 Gene	Presence of at least one functional copy of SMN1 exon 7	Homozygous deletion of SMN1 exon 7, confirming Spinal Muscular Atrophy (SMA)
G6PD Gene	Normal nucleotide sequence; adequate G6PD enzyme activity	Class I-IV pathogenic variants resulting in Glucose-6-Phosphate Dehydrogenase deficiency
F8 / F9 Genes	Intact gene sequences; normal coagulation factor VIII/IX activity	Inversions, deletions, or point mutations confirming Hemophilia A or B
LDLR Gene	Normal LDL receptor sequence and expression	Pathogenic variants causing Familial Hypercholesterolemia

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Monogenic Disorder Testing?

• Experienced Healthcare Professionals: Our molecular pathology department is staffed by highly trained geneticists, molecular biologists, and pathologists specializing in genetic interpretation.
• Patient-Focused Care: We prioritize patient comfort, confidentiality, and clear communication throughout the genetic testing journey.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, ensuring the highest accuracy in molecular diagnostics.
• Professional Reporting: Detailed clinical reports include comprehensive variant annotation, clinical correlation, and recommendations for further management.
• Modern Diagnostic Approach: We utilize state-of-the-art sequencing platforms and advanced bioinformatics pipelines to detect complex genetic variations.
• Comfortable Environment: Our diagnostic centers across Pakistan offer clean, professional, and welcoming environments for sample collection.
• Convenient Location: With an extensive network of collection centers nationwide, patients can access our services easily.
• Commitment to Accurate Diagnosis: We are dedicated to providing precise, evidence-based genetic results to guide personalized medical care.